Structure and ligand-binding mechanism of the human OX 1 and OX 2 orexin receptors

Nature Structural and Molecular Biology

Volumn 23, Issue 4, 2016, Pages 293-299

  Yin, Jie ^a   Babaoglu, Kerim ^b   Brautigam, Chad A ^a   Clark, Lindsay ^a   Shao, Zhenhua ^a   Scheuermann, Thomas H ^a   Harrell, Charles M ^b   Gotter, Anthony L ^b   Roecker, Anthony J ^b   Winrow, Christopher J ^b   Renger, John J ^b   Coleman, Paul J ^b   Rosenbaum, Daniel M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; NEUROPEPTIDE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; PROTEIN; PROTEIN PGS; SUVOREXANT; UNCLASSIFIED DRUG; [5 (2 FLUOROPHENYL) 2 METHYL 4 THIAZOLYL][2 [(5 PHENYL 1,3,4 OXADIAZOL 2 YL)METHYL] 1 PYRROLIDINYL]METHANONE; AZEPINE DERIVATIVE; LIGAND; OREXIN RECEPTOR; OREXIN RECEPTOR ANTAGONIST; PROTEIN BINDING; PYRROLIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; FEMALE; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION;

AZEPINES; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; OREXIN RECEPTOR ANTAGONISTS; OREXIN RECEPTORS; PROTEIN BINDING; PROTEIN CONFORMATION; PYRROLIDINES; THIAZOLES; TRIAZOLES;

EID: 84960155005     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.3183     Document Type: Article

References (65)

1. Marcus, J.N. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25 (2001).
2. Li, J., Hu, Z. &de Lecea, L. The hypocretins/orexins: integrators of multiple physiological functions. Br. J. Pharmacol. 171, 332-350 (2014).
3. Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998).
4. de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95, 322-327 (1998).
5. Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376 (1999).
6. Chemelli, R.M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451 (1999).
7. Willie, J.T. et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715-730 (2003).
8. Zheng, H., Patterson, L.M. &Berthoud, H.-R. Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. J. Neurosci. 27, 11075-11082 (2007).
9. Harris, G.C., Wimmer, M. &Aston-Jones, G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437, 556-559 (2005).
10. Boutrel, B. et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. USA 102, 19168-19173 (2005).
11. Bingham, S. et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92, 81-90 (2001).
12. Johnson, P.L. et al. A key role for orexin in panic anxiety. Nat. Med. 16, 111-115 (2010).
13. Winrow, C.J. &Renger, J.J. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br. J. Pharmacol. 171, 283-293 (2014).
14. Funato, H. et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 9, 64-76 (2009).
15. Xie, X. et al. Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J. Clin. Invest. 118, 2471-2481 (2008).
16. Aston-Jones, G., Smith, R.J., Moorman, D.E. &Richardson, K.A. Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56 (suppl. 1), 112-121 (2009).
17. Cui, J.J. et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54, 6342-6363 (2011).
18. Rosenbaum, D.M. et al. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318, 1266-1273 (2007).
19. Caffrey, M. Crystallizing membrane proteins for structure determination: use of lipidic mesophases. Annu. Rev. Biophys. 38, 29-51 (2009).
20. White, J.F. et al. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513 (2012).
21. Yin, J., Mobarec, J.C., Kolb, P. &Rosenbaum, D.M. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 519, 247-250 (2015).
22. Cox, C.D. et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320-5332 (2010).
23. Caffrey, M. &Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nat. Protoc. 4, 706-731 (2009).
24. Palczewski, K. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289, 739-745 (2000).
25. Hanson, M.A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851-855 (2012).
26. Cox, C.D. et al. Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorg. Med. Chem. Lett. 19, 2997-3001 (2009).
27. Langmead, C.J. et al. Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br. J. Pharmacol. 141, 340-346 (2004).
28. Tran, D.-T. et al. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur. J. Pharmacol. 667, 120-128 (2011).
29. Putula, J. &Kukkonen, J.P. Mapping of the binding sites for the OX1 orexin receptor antagonist, SB-334867, using orexin/hypocretin receptor chimaeras. Neurosci. Lett. 506, 111-115 (2012).
30. Heifetz, A. et al. Study of human Orexin-1 and-2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis. Biochemistry 51, 3178-3197 (2012).
31. Malherbe, P. et al. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: Comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol. Pharmacol. 78, 81-93 (2010).
32. Müller, C.E. &Jacobson, K.A. in Methylxanthines Vol. 200 (ed. Fredholm, B.B.) 151-199 (Springer, 2011).
33. Huang, S.-Y. &Zou, X. Scoring and lessons learned with the CSAR benchmark using an improved iterative knowledge-based scoring function. J. Chem. Inf. Model. 51, 2097-2106 (2011).
34. Li, Y., Han, L., Liu, Z. &Wang, R. Comparative assessment of scoring functions on an updated benchmark: Evaluation methods and general results. J. Chem. Inf. Model. 54, 1717-1736 (2014).
35. Friesner, R.A. et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49, 6177-6196 (2006).
36. Lyne, P.D., Lamb, M.L. &Saeh, J.C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J. Med. Chem. 49, 4805-4808 (2006).
37. Kim, H.-Y., Hong, E., Kim, J.-I. &Lee, W. Solution structure of human orexin-A: regulator of appetite and wakefulness. J. Biochem. Mol. Biol. 37, 565-573 (2004).
38. Lee, J.H. et al. Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B. Eur. J. Biochem. 266, 831-839 (1999).
39. Isberg, V. et al. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res. 42, D422-D425 (2014).
40. Rosenbaum, D.M. et al. Structure and function of an irreversible agonist-β2 adrenoceptor complex. Nature 469, 236-240 (2011).
41. Katritch, V., Cherezov, V. &Stevens, R.C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531-556 (2013).
42. Ye, N., Neumeyer, J.L., Baldessarini, R.J., Zhen, X. &Zhang, A. Update 1 of: recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 113, PR123-PR178 (2013).
43. Granier, S. et al. Structure of the δ-opioid receptor bound to naltrindole. Nature 485, 400-404 (2012).
44. German, N.A., Decker, A.M., Gilmour, B.P., Thomas, B.F. &Zhang, Y. Truncated orexin peptides: structure-activity relationship studies. ACS Med. Chem. Lett. 4, 1224-1227 (2013).
45. Kufareva, I. et al. Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation. Proc. Natl. Acad. Sci. USA 111, E5363-E5372 (2014).
46. Ahmed, S.S. et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci. Transl. Med. 7, 294ra105 (2015).
47. Zhao, H., Piszczek, G. &Schuck, P. SEDPHAT: a platform for global ITC analysis and global multi-method analysis of molecular interactions. Methods 76, 137-148 (2015).
48. Kobilka, B.K. Amino and carboxyl terminal modifications to facilitate the production and purification of a G protein-coupled receptor. Anal. Biochem. 231, 269-271 (1995).
49. Horcajada, C., Guinovart, J.J., Fita, I. &Ferrer, J.C. Crystal structure of an archaeal glycogen synthase: insights into oligomerization and substrate binding of eukaryotic glycogen synthases. J. Biol. Chem. 281, 2923-2931 (2006).
50. Karplus, P.A. &Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012).
51. Otwinowski, Z. &Minor, W. Processing of X-ray diffraction data. Methods Enzymol. 276, 307-326 (1997).
52. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
53. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
54. Cowtan, K. Fitting molecular fragments into electron density. Acta Crystallogr. D Biol. Crystallogr. 64, 83-89 (2008).
55. Emsley, P., Lohkamp, B., Scott, W.G. &Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
56. Painter, J. &Merritt, E.A. TLSMD web server for the generation of multi-group TLS models. J. Appl. Crystallogr. 39, 109-111 (2006).
57. Schüttelkopf, A.W. &van Aalten, D.M.F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
58. Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
59. Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R. &Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221-234 (2013).
60. Jakubík, J., El-Fakahany, E.E. &Doleẑal, V. Towards predictive docking at aminergic G-protein coupled receptors. J. Mol. Model. 21, 284 (2015).
61. Bowers, K.J., Chow, E., Xu, H. &Dror, R.O. Scalable algorithms for molecular dynamics simulations on commodity clusters. Proc. 2006 ACM/IEEE Conf. Supercomputing (IEEE, 2006).
62. Shrake, A. &Rupley, J.A. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. J. Mol. Biol. 79, 351-371 (1973).
63. Friesner, R.A. et al. Glide: a new approach for rapid, accurate docking and scoring.1.Method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749 (2004).
64. Hojayev, B., Rothermel, B.A., Gillette, T.G. &Hill, J.A. FHL2 binds calcineurin and represses pathological cardiac growth. Mol. Cell. Biol. 32, 4025-4034 (2012).
65. Keller, S. et al. High-precision isothermal titration calorimetry with automated peak-shape analysis. Anal. Chem. 84, 5066-5073 (2012).